Pilot assessment of clinical and laboratory manifestations dynamics in patients with moderate coronavirus disease-19 (COVID-19) during the first week of hospitalization


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Purpose: to evaluate clinical symptoms and laboratory parameters dynamics in patients with coronavirus disease-19 during hospitalization first week. Material and methods. The prospective study included 38 patients (21 women and 17 men) with moderate coronavirus disease-19. Questioning, clinical examination and laboratory parameters estimation were carried out. The European life quality questionnaire and health visual-analog scale (VAS) were used. General blood analysis was evaluated. Patients were examined at the hospitalization moment and after 7 days. Statistical analysis was carried out with Wilcoxon and McNemar's tests in critical p-value<0.050. Data were presented as median and quartiles. Results. Patients were hospitalized on average 7 (5+10) days after the disease onset. During the observation period there was decreasing number of patients' suffering from cough (from 27 to 21; p=0,041), breath shortness (from 15 to 8; p=0,045), anosmia (from 14 to 2; p=0,001), dysgeusia (from 10 to 2; p=0,027), weakness (from 30 to 17, p=0,002), headache (from 21 to 10; p=0,022), myalgia (from 11 to 3, p=0.013), nausea (from 9 to 3; p=0,041). Health general state improved from 60 (50+75) to 80 (55+87) points (p <0,001), discomfort feeling decreased from 2 (1+2) to 1 (1+2) points (p=0,025). During the week, hemoglobin concentration decreased from 137,5 (128,0+145,0) g/l to 125,5 (119,0+136,0) g/l (p <0,001) and the platelet count increased from 217,5 (179,0+279,0) 109/ l to 295,0 (235,0+367,0) 109/l (p=0,027). Conclusion. During the first week of hospitalization, weakness, headache, myalgia, breath shortness, cough, anosmia, dysgeusia, nausea regress, the hemoglobin level decreases, the platelet count increases moderately.

Texto integral

Acesso é fechado

Sobre autores

N. Izmozherova

Ural State Medical University of the Ministry of Healthcare of Russia

Email: nadezhda_izm@mail.ru
MD, head of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Artem Popov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: art_popov@mail.ru
MD, head of the Department of hospital therapy and urgent medical care service 620028, Yekaterinburg, 3 Repina Str

Andrey Tsvetkov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: cp-gendir@mail.ru
PhD, head of the Department of public welfare and public health 620028, Yekaterinburg, 3 Repina Str

Igor Borzunov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: ivborzunov@e1.ru
MD, professor of the Department of urology, nephrology and transplantology 620028, Yekaterinburg, 3 Repina Str

Alexander Stepanov

Central City Clinical Hospital No. 6

Email: mbucgkb6@mail.ru
Chief physician 620149, Yekaterinburg, 34 S. Deryabinoy Str

Elmira Prokopieva

Central City Clinical Hospital No. 6

Email: mbucgkb6@mail.ru
PhD, Deputy Chief physician 620149, Yekaterinburg, 34 S. Deryabinoy Str

Viktor Bakhtin

Ural State Medical University of the Ministry of Healthcare of Russia

Email: bakhtin.v95@mail.ru
postgraduate student of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Anna Vikhareva

Ural State Medical University of the Ministry of Healthcare of Russia

Email: anna1993vi@gmail.com
postgraduate student of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Leonid Kadnikov

Ural State Medical University of the Ministry of Healthcare of Russia

Email: kadn-leonid@mail.ru
resident of the Department of pharmacology and clinical pharmacology 620028, Yekaterinburg, 3 Repina Str

Bibliografia

  1. Fu L., Wang B., Yuan T. et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis. J Infect. 2020; 80(6): 656-65. doi: 10.1016/j.jinf.2020.03.041.
  2. Xie Y., Wang Z., Liao H. et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020; 20(1): 640. doi: 10.1186/s12879-020-05371-2.
  3. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 7 (03.06.2020). Доступ: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/ original/03062020_%D0%9CR_C0VID-19_v7.pdf (дата обращения - 09.01.2021).
  4. Costa K.V.T.D., Carnauba A.T.L., Rocha K.W. et al. Olfactory and taste disorders in COVID-19: a systematic review. Braz J Otorhinolaryngol. 2020; 86(6): 781-92. doi: 10.1016/j.bjorl.2020.05.008.
  5. Vaira L.A., Salzano G., Fois A.G. et al. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. Int Forum Allergy. Rhinol. 2020; 10(9): 1103-04. doi: 10.1002/alr.22593.
  6. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281-86. doi: 10.1007/s12098-020-03263-6.
  7. D'Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea during COVID-19 infection: Pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020; 18(8): 1663-72. doi: 10.1016/j.cgh.2020.04.001.
  8. Grassia R., Testa S., Pan A., Conti C.B. SARS-CoV-2 and gastrointestinal tract: The dark side of the pandemic. Dig Liver Dis. 2020; 52(7): 700-01. doi: 10.1016/j.dld.2020.04.028.
  9. Zhao Q., Fang X., Pang Z. et al. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020; 34(11): 2505-10. doi: 10.1111/jdv.16778.
  10. Matar S., Oules B., Sohier P. et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2020; 34(11): e686-e689. doi: 10.1111/jdv.16775.
  11. Wenzhong L., Hualan L. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. Available at: https://chemrxiv.org/articles/preprint/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173/9 (date of access - 09.01.2021). doi: 10.26434/ chemrxiv.11938173.v9.
  12. Cavezzi A., Troiani E., Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin. Pract. 2020; 10(2): 1271. doi: 10.4081/cp.2020.1271
  13. Soraya G.V., Ulhaq Z.S. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. Med Clin (Barc). 2020; 155(4): 143-51. doi: 10.1016/j.medcli.2020.05.017.
  14. Violi F., Pastori D., Cangemi R. et al. Hypercoagulation and antithrombotic treatment in coronavirus 2019: A new challenge. Thromb Haemost. 2020; 120(6): 949-56. doi: 10.1055/s-0040-1710317.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies